Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

Authors: Akintunde Akinleye, Parthu Avvaru, Muhammad Furqan, Yongping Song, Delong Liu

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate diverse cellular processes including proliferation, adhesion, survival, and motility. Dysregulated PI3K pathway signaling occurs in one-third of human tumors. Aberrantly activated PI3K signaling also confers sensitivity and resistance to conventional therapies. PI3K has been recognized as an attractive molecular target for novel anti-cancer molecules. In the last few years, several classes of potent and selective small molecule PI3K inhibitors have been developed, and at least fifteen compounds have progressed into clinical trials as new anticancer drugs. Among these, idelalisib has advanced to phase III trials in patients with advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. In this review, we summarized the major molecules of PI3K signaling pathway, and discussed the preclinical models and clinical trials of potent small-molecule PI3K inhibitors.
Appendix
Available only for authorised users
Literature
1.
Cantley LC: The phosphoinositide 3-kinase pathway. Science. 2002, 296 (5573): 1655-1657. 10.1126/science.296.5573.1655.PubMedCrossRef
2.
Burris HA: Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013, 71 (4): 829-842. 10.1007/s00280-012-2043-3.PubMedCrossRef
3.
Osaki M, Oshimura M, Ito H: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004, 9 (6): 667-676.PubMedCrossRef
4.
Akinleye A, Chen Y, Mukhi N, Song Y, Liu D: Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013, 6 (1): 59-10.1186/1756-8722-6-59.PubMedCentralPubMedCrossRef
5.
Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H: Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. J Hematol Oncol. 2012, 5 (1): 16-10.1186/1756-8722-5-16.PubMedCentralPubMedCrossRef
6.
Arteaga CL: Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. Curr Top Microbiol Immunol. 2010, 347: 189-208.PubMedCentralPubMed
7.
Sawyers CL: Will kinase inhibitors have a dark side?. N Engl J Med. 2006, 355 (3): 313-315. 10.1056/NEJMcibr062354.PubMedCrossRef
8.
Shaw R: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006, 441 (7092): 424-430. 10.1038/nature04869.PubMedCrossRef
9.
Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH, Auernhammer CJ: The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology. 2007, 85 (1): 54-60. 10.1159/000100057.PubMedCrossRef
10.
Patel S: Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway. Curr Oncol Rep. 2013, 15 (4): 386-395. 10.1007/s11912-013-0316-6.PubMedCrossRef
11.
Slomovitz B: The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012, 18 (21): 5856-5864. 10.1158/1078-0432.CCR-12-0662.PubMedCrossRef
12.
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ: High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304 (5670): 554-10.1126/science.1096502.PubMedCrossRef
13.
14.
Miller T: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011, 29 (33): 4452-4461. 10.1200/JCO.2010.34.4879.PubMedCentralPubMedCrossRef
15.
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L: High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007, 39 (3): 347-351. 10.1038/ng1975.PubMedCrossRef
16.
Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009, 9 (8): 550-562. 10.1038/nrc2664.PubMedCrossRef
17.
Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J: Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol. 2010, 21 (4): 683-691. 10.1093/annonc/mdp347.PubMedCrossRef
18.
Xu C, Zhou Q, Wu Y-l: Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? – A literature-based meta-analysis. J Hematol Oncol. 2012, 5 (1): 62-10.1186/1756-8722-5-62.PubMedCentralPubMedCrossRef
19.
20.
Brown JR, Furman RR, Flinn I, Coutre SE, Wagner-Johnston ND, Kahl BS, Spurgeon SEF, Benson DM, Peterman S, Johnson DM: Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory CLL. ASCO Meeting Abstracts. 2013, 31 (15_supp): 7003-
21.
Spurgeon E: Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110{delta} (PI3K{delta}), in patients with relapsed or refractory mantle cell lymphoma (MCL). ASCO Meeting Abstracts. 2013, 31 (15_suppl): 8519-
22.
Barrientos J: Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. J Clin Oncol. 2013, 31 (suppl): abstr 7017
23.
O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Holes L, Johnson DM, Gu J, Dansey RD: A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K{delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) >=65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ASCO Meeting Abstracts. 2013, 31 (15_suppl): 7005-
24.
25.
Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD: Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci. 1997, 22 (7): 267-272. 10.1016/S0968-0004(97)01061-X.PubMedCrossRef
26.
Engelman J: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006, 7 (8): 606-619. 10.1038/nrg1879.PubMedCrossRef
27.
Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD: Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001, 17: 615-675. 10.1146/annurev.cellbio.17.1.615.PubMedCrossRef
28.
Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM: Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol. 1998, 18 (3): 1379-1387.PubMedCentralPubMedCrossRef
29.
Backer JM: The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J. 2008, 410 (1): 1-17. 10.1042/BJ20071427.PubMedCrossRef
30.
Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, Stoyanova S, Vanhaesebroeck B, Dhand R, Nurnberg B: Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science. 1995, 269 (5224): 690-693. 10.1126/science.7624799.PubMedCrossRef
31.
Arcaro A, Zvelebil MJ, Wallasch C, Ullrich A, Waterfield MD, Domin J: Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol. 2000, 20 (11): 3817-3830. 10.1128/MCB.20.11.3817-3830.2000.PubMedCentralPubMedCrossRef
32.
Gaidarov I, Smith ME, Domin J, Keen JH: The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol Cell. 2001, 7 (2): 443-449. 10.1016/S1097-2765(01)00191-5.PubMedCrossRef
33.
Gaidarov I: Individual phosphoinositide 3-kinase C2alpha domain activities independently regulate clathrin function. J Biol Chem. 2005, 280 (49): 40766-40772. 10.1074/jbc.M507731200.PubMedCrossRef
34.
Volinia S, Dhand R, Vanhaesebroeck B, MacDougall LK, Stein R, Zvelebil MJ, Domin J, Panaretou C, Waterfield MD: A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. EMBO J. 1995, 14 (14): 3339-3348.PubMedCentralPubMed
35.
Stein MP, Feng Y, Cooper KL, Welford AM, Wandinger-Ness A: Human VPS34 and p150 are Rab7 interacting partners. Traffic. 2003, 4 (11): 754-771. 10.1034/j.1600-0854.2003.00133.x.PubMedCrossRef
36.
Carpenter CL, Auger KR, Chanudhuri M, Yoakim M, Schaffhausen B, Shoelson S, Cantley LC: Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem. 1993, 268 (13): 9478-9483.PubMed
37.
Arcaro A, Volinia S, Zvelebil MJ, Stein R, Watton SJ, Layton MJ, Gout I, Ahmadi K, Downward J, Waterfield MD: Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J Biol Chem. 1998, 273 (49): 33082-33090. 10.1074/jbc.273.49.33082.PubMedCrossRef
38.
Domin J, Pages F, Volinia S, Rittenhouse SE, Zvelebil MJ, Stein RC, Waterfield MD: Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J. 1997, 326 (Pt 1): 139-147.PubMedCentralPubMedCrossRef
39.
Turner SJ, Domin J, Waterfield MD, Ward SG, Westwick J: The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha. J Biol Chem. 1998, 273 (40): 25987-25995. 10.1074/jbc.273.40.25987.PubMedCrossRef
40.
41.
Furqan M, Mukhi N, Lee B, Liu D: Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Research. 2013, 1 (1): 5-10.1186/2050-7771-1-5.PubMedCentralPubMedCrossRef
42.
Lawlor M: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci. 2001, 114 (Pt 16): 2903-2910.PubMed
43.
Bea V: The PI3K-PDK1 connection: more than just a road to PKB. Biochem J. 2000, 346 (Pt 3): 561-576.
44.
Vivanco I: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2 (7): 489-501. 10.1038/nrc839.PubMedCrossRef
45.
Duronio V: The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J. 2008, 415 (3): 333-344. 10.1042/BJ20081056.PubMedCrossRef
46.
47.
Brunet A: Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol. 2001, 11 (3): 297-305. 10.1016/S0959-4388(00)00211-7.PubMedCrossRef
48.
Czech M: Signaling mechanisms that regulate glucose transport. J Biol Chem. 1999, 274 (4): 1865-1868. 10.1074/jbc.274.4.1865.PubMedCrossRef
49.
Kawakami Y, Kitaura J, Hata D, Yao L, Kawakami T: Functions of Bruton’s tyrosine kinase in mast and B cells. J Leukoc Biol. 1999, 65 (3): 286-290.PubMed
50.
Tuveson DA, Carter RH, Soltoff SP, Fearon DT: CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science. 1993, 260 (5110): 986-989. 10.1126/science.7684160.PubMedCrossRef
51.
Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR, Ohashi PS: Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med. 2000, 191 (10): 1721-1734. 10.1084/jem.191.10.1721.PubMedCentralPubMedCrossRef
52.
Radisavljevic Z: Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J Biol Chem. 2000, 275 (27): 20770-20774. 10.1074/jbc.M002448200.PubMedCrossRef
53.
Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP, King GL: Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem. 2000, 275 (52): 40725-40731. 10.1074/jbc.M006509200.PubMedCrossRef
54.
Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S: The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000, 19 (11): 2537-2548. 10.1093/emboj/19.11.2537.PubMedCentralPubMedCrossRef
55.
Clement S, Krause U, Desmedt F, Tanti JF, Behrends J, Pesesse X, Sasaki T, Penninger J, Doherty M, Malaisse W: The lipid phosphatase SHIP2 controls insulin sensitivity. Nature. 2001, 409 (6816): 92-97. 10.1038/35051094.PubMedCrossRef
56.
Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009, 16 (2): 115-125. 10.1016/j.ccr.2009.06.006.PubMedCentralPubMedCrossRef
57.
Blondeau F, Laporte J, Bodin S, Superti-Furga G, Payrastre B, Mandel JL: Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Hum Mol Genet. 2000, 9 (15): 2223-2229. 10.1093/oxfordjournals.hmg.a018913.PubMedCrossRef
58.
Bitting R: Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013, 20 (3): R83-R99. 10.1530/ERC-12-0394.PubMedCrossRef
59.
Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A, Saadati HR: Role of PTEN gene in progression of prostate cancer. Urol J. 2007, 4 (2): 95-100.PubMed
60.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B: Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010, 18 (1): 11-22. 10.1016/j.ccr.2010.05.026.PubMedCentralPubMedCrossRef
61.
Benistant C: A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene. 2000, 19 (44): 5083-5090. 10.1038/sj.onc.1203871.PubMedCrossRef
62.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL: An integrated genomic analysis of human glioblastoma multiforme. Science. 2008, 321 (5897): 1807-1812. 10.1126/science.1164382.PubMedCentralPubMedCrossRef
63.
Benson D: Final results of a phase I study of idelalisib, a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). ASCO Meeting Abstracts. 2013, 31 (15_suppl): 8526-
64.
Vadas O, Burke JE, Zhang X, Berndt A, Williams RL: Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal. 2011, 4 (195): re2-PubMedCrossRef
65.
66.
Arcaro A: Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J. 1993, 296 (Pt 2): 297-301.PubMedCentralPubMedCrossRef
67.
Liu Y: Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol. 2005, 12 (1): 99-107. 10.1016/j.chembiol.2004.11.009.PubMedCrossRef
68.
Nakamura M, Nakashima S, Katagiri Y, Nozawa Y: Effect of wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) on N-formyl-methionyl-leucyl-phenylalanine-induced phospholipase D activation in differentiated HL60 cells: possible involvement of phosphatidylinositol 3-kinase in phospholipase D activation. Biochem Pharmacol. 1997, 53 (12): 1929-1936. 10.1016/S0006-2952(97)00169-X.PubMedCrossRef
69.
70.
Marone R: Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2008, 1784 (1): 159-185. 10.1016/j.bbapap.2007.10.003.PubMedCrossRef
71.
Lannutti B: CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011, 117 (2): 591-594. 10.1182/blood-2010-03-275305.PubMedCentralPubMedCrossRef
72.
Herman SEM, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ: Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010, 116: 2078-2088. 10.1182/blood-2010-02-271171.PubMedCentralPubMedCrossRef
73.
Hoellenriegel J: The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011, 118 (13): 3603-3612. 10.1182/blood-2011-05-352492.PubMedCrossRef
74.
Meadows S: PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012, 119 (8): 1897-1900. 10.1182/blood-2011-10-386763.PubMedCrossRef
75.
76.
Coutre S: Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‑kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2011, 29: 6631-
77.
Furman R: CAL-101, an isoformselective inhibitor of phosphatidylinositol 3-kinase P110δ,demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood, (ASH Annual Meeting Abstracts). 2010, 160 (21): 55-
78.
Keating M: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002, 99 (10): 3554-3561. 10.1182/blood.V99.10.3554.PubMedCrossRef
79.
Lemery S: U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res. 2010, 16 (17): 4331-4338. 10.1158/1078-0432.CCR-10-0570.PubMedCrossRef
80.
Kahl B: Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma. ASH Annual Meeting Abstracts. 2010, 116 (21): 1777-
81.
Goy A: Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to Bortezomib: Phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013, 31: 3688-3695. 10.1200/JCO.2013.49.2835.PubMedCrossRef
82.
Kane R: Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007, 13 (18 Pt 1): 5291-5294.PubMedCrossRef
83.
Coutre S: Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study. Blood. 2012, 120: ASH Abstract No.191-
84.
Fischer K: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011, 29 (26): 3559-3566. 10.1200/JCO.2010.33.8061.PubMedCrossRef
85.
Bergmann M: Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica. 2005, 90 (10): 1357-1364.PubMed
86.
Furman R: A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia(CLL). J Clin Oncol. 2012, 30: 6518-
87.
Wierda W: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010, 28 (10): 1749-1755. 10.1200/JCO.2009.25.3187.PubMedCrossRef
88.
Eradat H: A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol. 2013, 31: TPS7133-
89.
Flinn I, 2013: A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol. 2013, 31: TPS7131-
90.
Leonard J: Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. J Clin Oncol. 2013, 31: 8500-
91.
Rummel M: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005, 23 (15): 3383-3389. 10.1200/JCO.2005.08.100.PubMedCrossRef
92.
De Vos S: A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). ASCO Meeting Abstracts. 2013, 31 (15): TPS8618-
93.
Leonard J: A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). J Clin Oncol. 2013, 31: TPS8617-
94.
Wagner-Johnston N: Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). J Clin Oncol. 2013, 31: 8501-
95.
Robinson K: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008, 26 (27): 4473-4479. 10.1200/JCO.2008.17.0001.PubMedCrossRef
96.
Burger J: Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA). J Clin Oncol. 2013, 31: TPS7130-
97.
Dartigeas C: Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Aged > 65 years : Results of a Multicenter Trial (LLC 2007 SA) On Behalf of the French Goelams/Fcgcll-WM Intergroup. Blood. 2012, 120: 434-
98.
Mulligan S: A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood. 2012, 120: 436-
99.
Burger M: Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett. 2011, 2 (10): 774-779. 10.1021/ml200156t.PubMedCentralPubMedCrossRef
100.
Zheng Y: Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl). 2012, 90 (6): 695-706. 10.1007/s00109-011-0849-9.CrossRef
101.
Meier F: The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo. ASCO Meeting Abstracts. 2013, 31 (15): e20050-
102.
Bradford L: Targeting the PI3K signaling cascade in PIK3CA mutated endometrial cancer in a primary human xenograft model. ASCO Meeting Abstracts. 2013, 31 (15): e13564-
103.
Bendell J: Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2012, 30 (3): 282-290. 10.1200/JCO.2011.36.1360.PubMedCrossRef
104.
Chakravarti A: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004, 22 (10): 1926-1933. 10.1200/JCO.2004.07.193.PubMedCrossRef
105.
Shih K: Phase I study of the combination of BKM120 and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM) or other refractory solid tumors. ASCO Meeting Abstracts. 2013, 31 (15): e13045-
106.
Wen P: Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). ASCO Meeting Abstracts. 2013, 31 (15): 2015-
107.
Mayer I: SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). J Clin Oncol. 2012, 30: 510-
108.
Iwata H: Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. ASCO Meeting Abstracts. 2013, 31 (15): TPS650-
109.
Tan D: A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC. J Clin Oncol. 2013, 31: 8107-CrossRef
110.
Folkes A: The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem. 2008, 51 (18): 5522-5532. 10.1021/jm800295d.PubMedCrossRef
111.
Junttila T: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009, 15 (5): 429-440. 10.1016/j.ccr.2009.03.020.PubMedCrossRef
112.
Garcia-Martinez J: Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer. 2011, 104 (7): 1116-1125. 10.1038/bjc.2011.83.PubMedCentralPubMedCrossRef
113.
Yao E: Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab. Clin Cancer Res. 2009, 15 (12): 4147-4156. 10.1158/1078-0432.CCR-08-2814.PubMedCrossRef
114.
Zou ZQ, Zhang LN, Wang F, Bellenger J, Shen YZ, Zhang XH: The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Molec Med Rep. 2012, 5 (2): 503-508.
115.
Li H, Wozniak A, Van Den Bossche K, Van Looy T, Wellens J, Stas M, Floris G, Friedman L, Debiec-Rychter M, Sciot R: Efficacy of the phosphoinositol 3 kinase (PI3K) inhibitor GDC-0941 in patient- and cell-line-derived xenografts of dedifferentiated liposarcoma (DDLPS). ASCO Meeting Abstracts. 2013, 31 (15): e13528-
116.
Floris G, Wozniak A, Sciot R, Li H, Friedman L, Van Looy T, Wellens J, Vermaelen P, Deroose CM, Fletcher JA: A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. Clin Cancer Res. 2013, 19 (3): 620-630. 10.1158/1078-0432.CCR-12-2853.PubMedCentralPubMedCrossRef
117.
Wagner A: A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol. 2009, 27: 3501-ASCO Annual Meeting ProceedingsCrossRef
118.
Von Hoff D: A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J Clin Oncol. 2011, 29: 3052-CrossRef
119.
Garcia V: A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. J Clin Oncol. 2011, 29: 3021-
120.
Baird R: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol (Meeting Abstracts). 2010, 28 (15): 2613-
121.
LoRusso P: A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J Clin Oncol. 2012, 30: 2566-10.1200/JCO.2012.42.1016.CrossRef
122.
Shapiro G: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol. 2011, 29: 3005-
123.
Besse B: A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2011, 29: 3044-10.1200/JCO.2011.35.1817.CrossRef
124.
Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G: The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther. 2005, 4 (9): 1349-1357. 10.1158/1535-7163.MCT-05-0149.PubMedCentralPubMedCrossRef
125.
Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R: Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther. 2004, 3 (7): 763-772.PubMed
126.
Jimeno A: Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. J Clin Oncol. 2010, 28 (15s): 3089-
127.
Jimeno A: PX-866 and docetaxel in patients with advanced solid tumors. J Clin Oncol. 2012, 30: 3024-
128.
Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Macdonald DR, Easaw JC, Eisenstat DD, Kakumanu AS, Squire J, Tsao MS: Phase II study of PX-866 in recurrent glioblastoma. ASCO Meeting Abstracts. 2013, 31 (15): 2053-
129.
Hotte SJ, Eisenhauer EA, Joshua AM, Kumar V, Ellard S, Gregg RW, Macfarlane RJ, Winquist E, Torri V, Ruether JD: NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). ASCO Meeting Abstracts. 2013, 31 (15): 5042-
130.
Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J, Dudley D: Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H–1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem. 2013, 56 (11): 4597-4610. 10.1021/jm4003632.PubMedCrossRef
131.
Staben ST, Ndubaku C, Blaquiere N, Belvin M, Bull RJ, Dudley D, Edgar K, Gray D, Heald R, Heffron TP: Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase beta isoform. Bioorg Med Chem Lett. 2013, 23 (9): 2606-2613. 10.1016/j.bmcl.2013.02.102.PubMedCrossRef
132.
Juric D: GDC-0032, a Beta Isoform-Sparing PI3K Inhibitor: Results of a First-in-Human Phase 1a Dose Escalation Study. Cancer Res (AACR Annual Meeting abstracts). 2013, 73: LB-64.
133.
Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM: BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110alpha and p110delta Activities in Tumor Cell Lines and Xenograft Models. Mol Cancer Ther. 2013, 12 (11): 2319-2330. 10.1158/1535-7163.MCT-12-0993-T.PubMedCrossRef
134.
Jeffers M: Evaluation of the PI3K inhibitor BAY 80–6946 in hematologic malignancies. J Clin Oncol. 2012, 30: e13576-
135.
Patnaik A, Ramanathan RK, Appleman LJ, Tolcher AW, Mountz JM, Beerham M, Weiss GJ, Rasco DW, Lotze MT, Toledo FG: Phase I Study of Intravenous PI3K Inhibitor Bay 80–6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort. ASH Annual Meeting Abstracts. 2012, 120 (21): 3704-
136.
Patnaik A: A first-in-human phase I study of intravenous PI3K inhibitor BAY 80–6946 in patients with advanced solid tumors: Results of dose-escalation phase. J Clin Oncol. 2011, 29: 3035-
137.
Lotze M: Phase I study of intravenous PI3K inhibitor BAY 80–6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts. J Clin Oncol. 2012, 30: 3019-
138.
Dunbar J: Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-{delta},{gamma}, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts). 2012, 120: 4853-
139.
Flinn I: Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-{delta},{gamma}, in Patients with Advanced Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts). 2012, 120: 3663-
140.
Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008, 7 (7): 1851-1863. 10.1158/1535-7163.MCT-08-0017.PubMedCrossRef
141.
Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68 (19): 8022-8030. 10.1158/0008-5472.CAN-08-1385.PubMedCrossRef
142.
Schnell CR, Stauffer F, Allegrini PR, O’Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, Garcia-Echeverria C: Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008, 68 (16): 6598-6607. 10.1158/0008-5472.CAN-08-1044.PubMedCrossRef
143.
Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008, 68 (22): 9221-9230. 10.1158/0008-5472.CAN-08-1740.PubMedCentralPubMedCrossRef
144.
Cao P, Maira SM, Garcia-Echeverria C, Hedley DW: Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer. 2009, 100 (8): 1267-1276. 10.1038/sj.bjc.6604995.PubMedCentralPubMedCrossRef
145.
Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK: NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 2009, 8 (8): 2204-2210. 10.1158/1535-7163.MCT-09-0160.PubMedCentralPubMedCrossRef
146.
Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, Garcia-Echeverria C, Mercuri M: NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Canc Res. 2010, 16 (2): 530-540. 10.1158/1078-0432.CCR-09-0816.CrossRef
147.
Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW: The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Canc Res. 2010, 16 (14): 3628-3638. 10.1158/1078-0432.CCR-09-3022.CrossRef
148.
Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O: Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Canc Res. 2011, 17 (8): 2373-2384. 10.1158/1078-0432.CCR-10-2289.CrossRef
149.
Arkenau H: The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors. J Clin Oncol. 2012, 30: 3097-
150.
Krop I: A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. J Clin Oncol. 2012, 30: 508-
151.
Salkeni M: A dose escalation, single arm, phase Ib/II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics, and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme. J Clin Oncol. 2012, 30: TPS3116-
152.
Salkeni M: BEZ235 in combination with everolimus for advanced solid malignancies: Preliminary results of a phase Ib dose-escalation study. J Clin Oncol. 2013, 31: e13518-
153.
Juric D: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res. 2012, 72 (8): 1-
154.
Cao Z: Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab. J Clin Oncol. 2013, 31: e13525-
155.
Gonzalez-Angulo A: Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study. J Clin Oncol. 2013, 31: 2531-
156.
Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D: Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012, 23 (9): 2399-2408. 10.1093/annonc/mds011.PubMedCrossRef
157.
Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY: Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Canc Res. 2011, 17 (22): 7116-7126. 10.1158/1078-0432.CCR-11-0796.CrossRef
158.
Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R: Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anti Canc Drugs. 2012, 23 (1): 131-138. 10.1097/CAD.0b013e32834c8683.CrossRef
159.
Glienke W, Maute L, Wicht J, Bergmann L: The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 2012, 33 (3): 757-765. 10.1007/s13277-011-0290-2.PubMedCrossRef
160.
Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J: PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011, 10 (11): 2189-2199. 10.1158/1535-7163.MCT-11-0185.PubMedCrossRef
161.
Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA: In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Mol Cancer Ther. 2011, 10 (8): 1440-1449. 10.1158/1535-7163.MCT-11-0240.PubMedCrossRef
162.
Millham R: First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. Mol Cancer Ther. 2011, 10 (1): 11-10.1186/1476-4598-10-11.CrossRef
163.
Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R, Gunzner J: Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem. 2011, 54 (21): 7579-7587. 10.1021/jm2009327.PubMedCrossRef
164.
Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J: GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011, 10 (12): 2426-2436. 10.1158/1535-7163.MCT-11-0446.PubMedCrossRef
165.
Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X: Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metabol Dispos: The Biological Fate of Chemicals. 2012, 40 (9): 1785-1796. 10.1124/dmd.112.046052.CrossRef
166.
Dey N: A combination of dual PI3K-mTOR inhibitor, GDC-0980, with PARP inhibitor plus carboplatin blocked tumor growth of BRCA-competent triple-negative breast cancer cells. J Clin Oncol. 2013, 31: 2613-
167.
Wagner AJ: A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol. 2011, 29: 3020-
168.
Funke R: A phase Ib/II study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate versus abiraterone acetate. J Clin Oncol. 2012, 30: TPS2616-
169.
Knight S: Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett. 2010, 1 (1): 39-43. 10.1021/ml900028r.PubMedCentralPubMedCrossRef
170.
Munster P: Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). J Clin Oncol. 2011, 29: 3018-
171.
Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I: Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 2010, 53 (6): 2636-2645. 10.1021/jm901830p.PubMedCrossRef
172.
Millham R: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. Mol Cancer Ther. 2011, 10 (11): 1-
173.
Garcia-Echeverria C, Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008, 27 (41): 5511-5526. 10.1038/onc.2008.246.PubMedCrossRef
174.
Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K, Korn WM: Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl). 2011, 89 (9): 877-889. 10.1007/s00109-011-0774-y.CrossRef
175.
Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT: Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011, 13 (4): 384-392. 10.1093/neuonc/noq193.PubMedCentralPubMedCrossRef
176.
LoRusso P: A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. J Clin Oncol. 2009, 27 (15s): 3502-
177.
Cohen R: A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol. 2010, 28 (15s): 3015-
178.
Nghiemphu P: A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. J Clin Oncol. 2010, 28 (15s): 3085-
179.
Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A. 2012, 109 (8): 2718-2723. 10.1073/pnas.1018001108.PubMedCentralPubMedCrossRef
180.
Edelman G: A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol. 2010, 28 (15s): 3004-
181.
Moldovan C: A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors. J Clin Oncol. 2010, 28 (15s): 3070-
182.
Traynor A: A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol. 2010, 28 (15s): 3078-
183.
Cloughesy T: Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. J Clin Oncol. 2013, 31: 2012-
184.
Firer M, Gellerman G: Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012, 5 (1): 70-10.1186/1756-8722-5-70.PubMedCentralPubMedCrossRef
185.
186.
Wang K, Wei G, Liu D: CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012, 1 (1): 36-10.1186/2162-3619-1-36.PubMedCentralPubMedCrossRef
187.
Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath S, Liu D: Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol. 2012, 5 (1): 21-10.1186/1756-8722-5-21.PubMedCentralPubMedCrossRef
188.
189.
Metadata
Title
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Authors
Akintunde Akinleye
Parthu Avvaru
Muhammad Furqan
Yongping Song
Delong Liu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-88

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Case report

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature

Research

Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models

Short report

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

Research

Epigenetic inactivation of the MIR129-2 in hematological malignancies

Review

Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers

Research

Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits